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Since the early groundbreaking experiments, this ex-
ploding field has been propelled by our appreciation for
the complexity of cancer, our thirst to understand theGenetically engineered mouse models have contrib-
uted extensively to the field of cancer research. The molecular and cellular basis for its development, our
desperate need for better preclinical models to testability to manipulate the mouse germline affords nu-
merous approaches toward understanding the com- novel treatment and prevention strategies, and the de-
velopment of increasingly refined technologies for ma-plexities of this disease, possibly providing accurate
preclinical models for therapeutic and diagnostic ad- nipulating gene expression and mutation in the mouse.
This review highlights some of the current strategies forvances. This review highlights some of the current
strategies for modeling cancer in the mouse, recent modeling cancer in the mouse, some recent accomplish-
ments in the field, and important remaining challenges.accomplishments, and key remaining challenges.
It is not intended to be comprehensive, and the reader
is encouraged to explore other recent reviews (HannIn the 17th Century, it was quite simple to make a mouse.
and Balmain, 2001; Kumar et al., 1995; Attardi and Jacks,According to the famous alchemist/chemist Jean Bab-
1999; Berns, 1999, 2001; Resor et al., 2001; Clarke, 2000;tista Van Helmont, all you had to do was stuff a sweaty
Macleod and Jacks, 1999). This review specifically doesshirt into a flask of wheat and incubate for three weeks.
not cover the critical area of genetic background differ-Two centuries later, Louis Pasteur pointed out that the
ences in cancer modeling and the importance of geneticonly proof in this finding was that experiments are easy
modifiers, because these subjects are addressed byto do—it’s the irreproachable experiments that are hard.
Balmain in this issue (2002). The reader is also referredNow, in the 21st Century, the recipes for mouse making
to the review by Lowe on chemotherapy, which dis-have become highly sophisticated; and, although the
cusses the use of mouse models in examining mecha-resulting studies have indeed been hard, they have
nisms of drug sensitivity and resistance (Johnstone etdoubtlessly proven to be fruitful. Notably, genetically
al., 2002 [this issue of Cell]).engineered mouse (GEM) models have contributed ex-
tensively to the field of cancer research. Understanding
the complexities of cancer demands a versatile experi- A Basic Strategy
mental approach within the context of the whole animal. There have now been hundreds of experiments that
More than 100 distinct cell types are susceptible to can- broadly alter cancer genes throughout a tissue (e.g.,
cer, and tumors are often heterogeneous, evolving through cell-specific transgene expression; Figure 1A)
through mechanisms that arise from intricate interac- or the entire organism (e.g., targeted germline muta-
tions between the emerging tumor and its “host.” Fur- tions; Figure 1B). These experiments have helped define
thermore, although cancer is generally rooted in highly the cellular responses to each specific alteration, as well
potent mutations to cellular genes such as oncogenes as the susceptible target cells. Through this approach
and tumor suppressor genes (TSG), more subtle and we have learned about the basic mechanisms that con-
complex genetic interactions within each individual can fer selective advantages to tumor cells, such as disrup-
strongly influence susceptibility to the disease (see Bal- tion of major cell cycle regulatory genes resulting in
main, 2002 [this issue of Cell]). aberrant proliferation (e.g., by altering the regulation of
In the early 1980s, soon after recombinant genes were pRb), interference with cell cycle checkpoints (e.g., p53,
first introduced into the mouse germline, single onco- ATM) and DNA integrity maintenance genes (e.g., mis-
genes were shown to predispose transgenic mice to match repair genes, BRCA1 and 2) to sustain the propa-
cancer. For example, the expression of c-Myc in mam- gation of damaged cells, and by inhibition of apoptotic
mary epithelium predisposed mice to mammary adeno- pathways (e.g., by bcl2 overexpression, p53 disruption).
carcinoma, and SV40 T antigen (T-Ag) expressed in brain Many more studies will be required to fully define the
epithelium led to brain cancer. Many experiments of role of existing and newly defined cancer genes in multi-
this sort followed and collectively proved that proper ple cell types. While information gained from these stud-
manipulation of the mouse germline could predispose ies will be broadly transferable to the human setting, it
the animal to cancer (Adams and Cory, 1991). The mid must be noted that species-specific differences do exist
to late 80s brought the discovery of TSGs as well as in the role of different genes in different cell types, which
can lead to different mutant phenotypes in the two spe-
cies (Jacks, 1996).3 Correspondence: tvdlab@med.unc.edu
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Figure 1. Strategies for Modeling Cancer in the Mouse
Many of the current approaches for creating mice with specific genetic lesions and the resulting potential for cell specificity of alterations are
diagrammed. The methods involve either the production of transgenic mice with random gene insertions, usually by pronuclear DNA injection
(in the diagram, mice with tails), or of mice with targeted mutations of endogenous genes via embryonic stem (ES) cell manipulation (designated
by mice without tails). Basic strategies are shown in (A) and (B), respectively. A gene of interest (GOI), for example an oncogene, can be
expressed cell specifically in transgenic mice using a cell specific promoter (CSP) (A). While the gene is present in every cell and thus
transmitted through the germline, expression is most often dictated by the associated regulatory elements, but can be influenced by the
site(s) of random insertion. Generally, expression is not achieved in every cell, but is usually widespread (as indicated by the light blue nuclei).
Careful assessment of each founder line is required to ascertain the extent and specificity of expression. Standard targeting strategies in ES
cells can be used to alter endogenous genes to create null (knock-out, as diagrammed in [B]) or other specific mutations (knock-in). In this
case, a mouse strain is generated that carries the engineered alteration in every cell (designated by an asterisk); cell specificity of expression
is dictated by the endogenous regulatory signals. Strategies in (C)–(G) offer conditional control of either transgene expression (C–E) or
endogenous gene mutation (F and G). In (C), the GOI is regulated by transcriptional response elements (RE) of a transcriptional activator (TA)
that is expressed in transgenic mice via a CSP. In the most versatile cases (e.g., tetracycline-regulated activator, lac-I repressor, ecdysone
receptor), TA function can be regulated by introduction of a small molecule. In this case, expression of the transgene is reversible, and the
effects of expression or expression cessation can be assessed at specific times. Cell specificity is dictated by a CSP driving the TA. Since
regulation is at the level of transcription, stability of the transgenic protein must be considered when assessing the effect of shut off. Activity
of the transgenic protein can be regulated when using the strategy depicted in (D). In this case, the GOI is fused to a segment encoding a
ligand-regulated protein domain. For example, the estrogen receptor ligand-binding domain has been used effectively to regulate transgenic
proteins. Strategies in (E)–(G) utilize a recombinase (xase) and its cognate binding site (yellow triangles) to induce deletions resulting in
expression of a transgene (E), an endogenous gene (G), or in a specific mutation (F). The recombinase can be introduced by crosses with
transgenic mice expressing the xase cell specifically (as in [A]–[C]) or by limited introduction via injection into a specific organ. In the latter
case, viral vectors have been used to successfully introduce the xase. However, it may be possible to introduce the protein directly if it is
modified appropriately. By introducing the xase somatically, it is possible to achieve the desired alteration in a limited number of cells so as
to model the stochastic nature of events that produce cancer in humans. Finally, many of these strategies can be used in combination to
achieve even greater control of where and when desired changes occur. In diagrams of a simple tissue with two cell types present, cells
expressing a transgene or harboring an expressed lesion harbor light blue nuclei. In (B), an asterisk indicates cells carrying a specific targeted
mutation. Increased cell numbers indicate a potential cellular oncogenic response.
In addition to establishing cause and effect relation- al., 1994, and references therein). These responses pre-
dispose to the focal emergence of tumors, a sign thatships, broad alteration of cancer genes in the mouse
has also provided the foundation for studying tumor additional events have occurred in a subset of aberrant
cells to advance the development of tumors (Lu et al.,evolution. Reflecting the multistep process of cancer
development, a single alteration in the mouse is gener- 2001). Combining multiple events within the same cells
by intercrossing independently derived mouse strainsally not sufficient to elicit a full tumorigenic response.
For example, widespread expression of T121 (a truncated provides a powerful genetic approach for determining
the specific collaborating events in tumorigenesis. Be-T-Ag that inactivates pRb and related proteins, p130
and p107) in brain epithelium initially results in aberrant yond extending our understanding of the effects elicited
by each alteration, these experiments have shown usproliferation, apoptosis, and hyperplasia (Symonds et
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that the order of events matters in the evolution of a mal mammalian environment. Moreover, the ability to
tumor. For example, while p53-deficient mice rarely de- manipulate the embryo and several adult tissues to pro-
velop epithelial cell tumors, p53 inactivation can have duce mosaic mice and organs facilitates the assessment
profound effects on the development of such tumors of distinct cellular compartments.
when they are initiated by distinct oncogenic events To identify genes involved in tumor progression, tu-
(Tien et al., 1999; Lozano and Liu, 1998). In the example mors from GEM models have been analyzed for the
cited above, p53 inactivation accelerates tumor growth spontaneous accumulation of common genetic lesions
because the apoptosis induced by pRb pathway aberra- corresponding to key transitions in tumorigenesis. For
tion is largely p53 dependent (Symonds et al., 1994). example, Rip-Tag mice expressing the SV40 T-Ags in
Since tumor evolution results from genetic and/or epige- pancreatic islet cells undergo tumorigenesis through de-
netic alterations that provide selective advantages to fined stages that coincide with shifts in proliferation,
the cell in its microenvironment, it follows that each apoptosis, and angiogenesis (Bergers et al., 1998; Ca-
event in tumor evolution will set the stage for subsequent vallaro and Christofori, 2000). Simple sequence length
events. Thus, the specific combination of mutations and polymorphism analysis showed that two common re-
the mechanisms by which they fuel tumorigenesis may gions of LOH occurred preferentially in tumor cells at
vary depending on the cell type and the preceding onco- different stages (Parangi et al., 1995). Recently, the limits
genic event(s). Combining mutations in mice has pro- of these regions have been further refined, and addi-
vided an important tool with which to understand these tional regions of copy number changes detected, using
dynamics, though much more work is needed before array-based comparative genomic hybridization analy-
unifying principles are fully understood. sis (Hodgson et al., 2001). Identification of specific genes
As in other genetic systems, combining multiple muta- involved in tumor progression by assessment of ran-
tions within the same mouse has also been used to domly occurring mutations has been a slow process,
delineate molecular pathways. For example, pathway limiting the number of comprehensive studies to date;
analyses have helped sort through the complexities of however, recent advances in mouse genome informatics
p53 tumor suppression mechanisms. Since p53 partici- and technology will accelerate these efforts (see below).
pates in many biological responses, its specific role in Recent progress has been made in the effort to under-
suppressing tumors of various cell types must be di- stand angiogenesis and invasion by genetically as-
rectly analyzed in vivo to ascertain the relevant pathway sessing the roles of genes with altered expression pat-
and biological function. Importantly, such studies have terns at specific tumor stages. For example, in the Rip-
shown that the mechanisms and pathways can vary Tag model, loss of E cadherin expression accompanies
depending on the cellular context. In the brain epithelial the transition from adenoma to invasive carcinoma. In-
model described above, apoptosis is reduced and tumor tercrosses with transgenic mice that expressed E cadh-
growth is accelerated in the absence of p53, providing erin in pancreatic  cells arrested tumorigensis at the
an assay for p53 tumor suppression. By examining the adenoma stage, while expression of a dominant-nega-
apoptosis and tumor growth rates in mice harboring tive inhibitor accelerated invasion and metastasis (Perl
other deficiencies, a pathway has been defined in which et al., 1998). Metastasis could also be enhanced in this
E2F1 induces p53-mediated apoptosis that is partially model by inactivation of N cam, which apparently func-
dependent on Bax induction (Pan et al., 1998; Yin et al., tions in tumor cells to activate signaling through FGFR-4
1997). Atm and Arf, upstream regulators of p53 in other (Cavallaro et al., 2001, and references therein). The tran-
systems, are both dispensable for p53 tumor suppres- sition to angiogenesis in the Rip-Tag model is accompa-
sion in this context (Liao et al., 1999; Tolbert et al., 2002). nied by expression of the matrix metalloprotienase,
In contrast, similar genetic analyses have shown that MMP-9. On an MMP-9-deficient background, the num-
Arf has a role in p53-dependent apoptosis and tumor ber of angiogenic islets, as well as the overall tumor
suppression in B cells (Schmitt et al., 1999; Eischen
burden, are reduced (Bergers et al., 2000). In a distinct
et al., 1999). The importance of pathway and cell type
model of tumor progression, squamous cell carcinoma
specificity was also demonstrated in studies that exam-
initiated by basal keratinocyte expression of HPV E6ined the effect of cyclin D1 mutation in mammary tumori-
and E7 is also suppressed in MMP-9/ mice. Remark-genesis initiated by various oncogenes. While activated
ably, the tumor-enhancing functions of MMP-9 couldRas or Neu required cyclin D1 for tumor initiation, c-Myc
be restored by transplanting bone marrow from wild-and Wnt-1 did not. Furthermore, although Cyclin D1 was
type mice, indicating a non-cell-autonomous influencerequired for Ras to predispose mammary epithelium to
of stromal cells on tumor growth (Coussens et al., 2000).tumorigenesis, it was dispensable for Ras-induced skin
These experiments further emphasize that studies intumors (Yu et al., 2001, and references therein).
mice in which every cell has the same alteration, as inAlthough much has been learned about the early
knock-out mice (Figure 1B), must be interpreted cau-stages of tumorigenesis using mouse models, we know
tiously. Since cancer in humans never develops in suchlittle about the molecular and cellular mechanisms of
a background, the impact of lesions limited to specificangiogenesis, invasion, and metastasis. From a human
cells of origin must also be explored (see below).health perspective, these aspects of cancer develop-
ment are perhaps the most critical to understand, and
Modeling Cancer through Complexyet are the most challenging in that they involve complex
Genetic Strategiescell-cell and cell-microenvironment interactions. Here,
On/Off Conditional Systemsuse of the mouse provides an advantage beyond the
To examine the impact of oncogene expression duringability to manipulate the genome. Experiments in the
mouse enable assessment of cellular changes in a nor- distinct developmental stages, and to explore the re-
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quirement for sustained oncogene activity, several in- genic responses were also evoked in the dermis by
TGF-1 expression in the epidermis using a bitransgenicvestigators have pioneered the use of reversible strate-
gies for transgene expression in vivo (Figures 1C and system in which transgene expression was controlled
by a GAL 4/progesterone receptor fusion and topical1D). One successful approach has utilized the tetracy-
cline-inducible system established by Bujard (reviewed application of antiprogestin (Wang et al., 1999). These
studies emphasize the complex, often multifactorial, ef-in Baron and Bujard, 2000). By this strategy, the gene
to be expressed is regulated under the tet operator, and fects caused by single genetic events, both cell autono-
mously and within the microenvironment.the tet-regulated transcriptional activator is provided
under the control of a cell-specific promoter, usually by Cell-Specific Targeted Mutations
As indicated above, mutation of a gene throughout theintercrosses to produce bitransgenic mice. The mice
are then fed doxycycline (dox), a derivative of tetracy- mouse by targeted mutagenesis of ES cells cannot
model the development of sporadic cancer, which arisescline, to either induce or repress transgene expression
depending on the system used. Another successful ap- amidst a genetically “normal” background. Furthermore,
many germline TSG-null or oncogene-activating muta-proach has been to generate fusion proteins between
the oncoprotein and the estrogen receptor, allowing ac- tions cause lethality due to phenotypes unrelated to the
cell type of interest. While the construction of chimerictivation of the protein by treatment with tamoxifin.
Though reported studies using reversible strategies are mice, consisting of both normal and mutant cells, can
overcome the problem of embryonic lethality and allowfew so far, significant findings have already emerged.
First, sustained tumorigenic responses generally de- for development of new tumor models (Cichowski et al.,
1999), this strategy is limited by the inability to breedpend on the continuous presence of oncogene activity.
For example, use of the tet-regulatable system showed mice with the relevant genotype. To circumvent these
issues, “conditional” strategies that rely on recombi-that the development and maintenance of melanoma
by activated Ha-ras and Ink4a/Arf deficiency required nase-mediated cell-type specific genetic deletion have
been developed (Figures 1E–1G). The region to be de-sustained expression of Ras (Chin et al., 1999). Dox-
induced expression of activated K-ras in lung epithelium leted is flanked by recombinase sites (loxP or frt) in such
a way that does not disrupt expression of the wild-typepredisposed mice to lung adenocarcinoma, a phenotype
that was accelerated in mice deficient for p53 or Ink4a/ gene. The respective recombinase (Cre or Flp) can then
be introduced via intercrosses with transgenic mice thatArf; all tumors regressed upon inhibition of Ras expres-
sion (Fisher et al., 2001). Similarly, leukemia induced by have been engineered to express it cell specifically or
via somatic delivery (see below and Figure 1). Severalthe BCR-ABL 1 (Huettner et al., 2000) and leukemias
and T cell lymphomas induced by Myc (Felsher and examples of this approach have recently demonstrated
its utility in cancer modeling. For example, mice nullizy-Bishop, 1999) regressed upon shut off of the respective
oncogene. The use of a myc-ER transgene also showed gous for either Brca1 or Brca2 die early in embryogene-
sis, and heterozygous mice are not predisposed to tu-that premalignant changes in the skin were dependent
upon sustained Myc activity (Pelengaris et al., 1999). morigenesis as are humans harboring a mutation in one
allele of either gene. However, conditional mutation ofLikewise, tet-regulated FGF-7 expression induced lung
epithelial cell proliferation and hyperplasia dependent either gene in the mammary epithelium promotes mam-
mary tumorigenesis. Mutation of Brca1 predisposes toupon sustained expression (Tichelaar et al., 2000). These
studies have important implications for the development mammary tumors with long latency and low frequency.
Tumors harbor rearrangements of chromosome 11,of antitumor therapies, suggesting that initial oncogenic
insults constitute viable targets. Interestingly, examina- prompting assessment of Brca1 conditional mutation in
a p53 heterozygous background. Indeed, tumors weretion of SV40 T-Ag in the salivary gland using a tet-re-
pressible system showed that hyperplasia was revers- accelerated, and most tumors had lost the wild-type
p53 allele (Xu et al., 1999). Conditional inactivation ofible if expression was inhibited within 4 months, but not
beyond 7 months, of hyperplastic development (Ewald either Brca2 or p53 was not sufficient to predispose
mice to mammary gland tumors; however, conditionalet al., 1996). Persistence of polyploidy at later times
indicated that genetic changes could have occurred that inactivation of both Brca2 and p53 caused a high fre-
quency of mammary tumors (Jonkers et al., 2001). Thesecircumvented the need for T-Ag. T-Ag expression was
not detectable; however, the possibility of undetectable studies implicate synergistic effects of Brca and p53
mutations, which may reflect the need for checkpointlevels of expression represents an impediment to firm
conclusions. mutations (e.g., in p53) to sustain cells with chromo-
somal aberrations caused by Brca1 or Brca2 impairmentBeyond establishing the need for sustained oncogene
expression to support tumor maintenance in these sys- (see accompanying review by Venkitaraman in this issue
[Venkitaraman, 2002]). Somatic inactivation of the Rbtems, the ability to examine direct effects of oncogene
expression and shut off has provided mechanistic in- gene has been used to generate a model of medulloblas-
toma (Marino et al., 2000). In this case, Cre was ex-sight to their contribution. For example, the earliest
measurable effect of inhibiting Ras expression in mela- pressed under the glial fibrillary acidic protein promoter,
and precursor cells of the external granular layer ap-nocytes was destruction of the tumor vasculature, sup-
porting the possibility that Ras expression in tumor cells peared to be the responsive target. Tumors were in-
duced only when cells were also deficient in p53, eitherelicits non-cell-autonomous responses in the vascula-
ture (Chin et al., 1999). Similarly, Myc expression in the in a p53-null background or upon conditional deletion
of p53 alleles. Interestingly, although Rb was mutatedepidermis, in addition to activating proliferation and dis-
rupting differentiation of keratinocytes, also induced an- in astrocytes as expected, these cells were unaffected.
Another important breakthrough in appropriate model-giogenesis in the skin (Pelengaris et al., 1999). Angio-
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ing of a human cancer was achieved by cell-specific 2001). Removal of the stop element and activation of
inactivation of the Nf2 gene. Humans who inherit a mu- K-ras was accomplished by a recombinant Cre adenovi-
tant Nf2 allele most frequently develop schwanomas or rus delivered to the lungs, resulting in lung tumors. The
meningiomas, whereas mice heterozygous for a mutant use of recombinant adenovirus to deliver Cre was first
Nf2 allele develop mostly osteosarcomas and not described by Shibata (Sweeney et al., 1999) in the devel-
schwannomas (McClatchey et al., 1998). Nf2 null mice opment of a colon cancer model involving conditional
die early in embryogenesis. However, when the Nf2 gene mutant Apc alleles. These approaches can be extended
was deleted specifically in Schwann cell precursors by to other oncogenes and TSGs, alone or in combination,
cell-specific transgenic Cre expression, mice were pre- to model other types of sporadic human cancer.
disposed to schwannoma and also developed additional
characteristics of the human disease (Giovannini et al., Measuring Success
2000). With all of this technical wizardry, how do we measure
Induction of Restricted Somatic Mutations success? While a simple question on the surface, in fact
It is clear that cell-specific somatic mutation of genes it has become a complex and somewhat vexing problem
provides an important avenue for modeling and explor- for the field. On one level, success can be measured by
ing cancer. Yet, the approaches described above still the amount of knowledge gained about the properties
alter a gene broadly throughout a given tissue, affecting of cancer cells and cancer-associated genes from stud-
thousands of cells simultaneously (see Figure 1). To ies in these mouse models. And here there is no doubt
most accurately model sporadic cancer, mutations that a great deal has been learned, and there is much
should arise in a limited number of cells. To this end, more to come. But while these basic science advances
somatic delivery of oncogenes or recombinases to a have clear importance for our ultimate understanding
restricted number of cells has been developed. So far, of the tumorigenic process, there is a common (and not
these experiments have used viral vectors to deliver unreasonable) expectation that these mouse models will
genes to somatic cells. One system has been engi- “model” human cancer; that is, cancer in the mouse
neered to facilitate cell-specific delivery of genes by should look and act like the human disease. Mouse
avian retroviruses (Fisher et al., 1999). Transgenic mice tumors should have the same or similar histological fea-
express the avian retrovirus receptor (TVA) cell specifi- tures of comparable human tumors; they should prog-
cally, such that introduction of a recombinant avian ret- ress through the same stages and cause the same physi-
rovirus results in restricted infection. Since the virus can ological and systemic effects on the host; the same
be delivered directly into the target tissue, a limited genes and/or pathways should be affected in tumor
number of cells can be infected. This strategy has been initiation and progression; the response of a given tumor
used extensively to explore the effect of specific onco- to a particular therapy in the mouse should accurately
genes in multiple cell types of the brain. In mice that reflect the response in human patients; and the results
express TVA in neural precursors under the nestin pro- from preclinical testing of experimental therapies in
moter, activated K-ras and AKT induce glioblastoma mouse models should ultimately predict the efficacy of
(Holland et al., 2000) and PDGF induces oligodendrogli-
such therapies in clinical trials in humans.
oma (Dai et al., 2001). A variation of this approach was
In part to address the degree to which current mouse
recently used to generate mouse tumors resembling
cancer models satisfy these criteria, as well as to spur
human ovarian carcinomas. Since no ovary-specific pro-
the development of more sophisticated models, the Na-moter has been identified, ovarian cells expressing TVA
tional Cancer Institute (NCI) established the mouse mod-under a more general promoter were infected in vitro
els of human cancer consortium (MMHCC) in 1999. Theand cells were then transferred into recipient mice. p53-
MMHCC consists of 20 funded grants, with each grantdeficient ovarian cells that received any paired combina-
composed of multiple investigators typically covering ation of c-myc, Akt, or activated K-ras were tumorigenic
range of expertise in mouse modeling and analysis aswhen transplanted into the ovarian bursa of recipient
well as in human cancer. In addition to their principlemice. Importantly, these tumors were metastatic to sites
activities of model building and characterization, thecharacteristic of the human disease (Orsulic et al., 2002).
MMHCC investigators (along with the NCI) have alsoMice have been engineered to have an increased
been active in bringing together investigators fromprobability of expressing activated K-ras by inserting a
throughout the international mouse modeling commu-duplication containing an oncogenic mutation into the
nity with veterinary and clinical pathologists, experts inendogenous allele. Spontaneous recombination within
human cancer biology and treatment as well as repre-the allele can result in expression of the mutant protein.
sentatives of the pharmaceutical and biotechnology in-These mice are predisposed to a variety of tumors, most
dustries. Through a series of workshops, these groupspredominantly lung adenocarcinomas (Johnson et al.,
have begun to address questions ranging from how dif-2001). Because tumorigenesis arises spontaneously in
ferent mouse models of a given tumor type (or subtype)a limited number of cells, and yet the initiating lesion
resemble each other and how they resemble the cognateis known, these mice provide a valuable resource for
human disease to what considerations should go intomechanistic exploration as well as for preclinical thera-
selecting a model for preclinical evaluation of differentpeutic testing (see below). Additional models have been
classes of anticancer agents. For most tumor types,developed recently that use recombination to limit the
there has been a consensus that the existing GEM mod-activation of the K-ras oncogene to specific cells. These
els can effectively model the human disease, especiallyemploy transcriptional stop elements flanked by loxP
the earlier stages, and that the newest approaches havesites upstream of an oncogenic K-ras allele (as depicted
in Figure 1G; Meuwissen et al., 2001; Jackson et al., the potential to create even more accurate models. Sum-
Cell
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maries of these workshops and additional information end stages. Moreover, for many mouse models, animals
die or must be sacrificed due to the effects of the primaryabout the MMHCC is available at their website (http://
tumor(s) such that the tumor may not have time to prog-emice.nci.nih.gov/). In addition, the MMHCC is building
ress to later stages. To address this problem, severala database for all mouse cancer models (also found at
approaches have been developed in recent years tohttp://emice.nci.nih.gov/), which should serve to catalog
increase the mutation rate in cancer-prone cells withmodels and their phenotypes as well as to allow investi-
the aim to accelerate tumor progression. An added ben-gators to post their experiences in using the models for
efit for many of these methods is that they should facili-various purposes. Finally, the MMHCC has established
tate the discovery of genes involved.a repository for mouse cancer models at the NCI cam-
One powerful strategy addresses the fact that mousepus at Frederick, MD. Inquiries for obtaining or sub-
cells, unlike human cells, have relatively long telomeresmitting strains can be made at http://web.ncifcrf.gov/
that protect against end-to-end fusions and subsequentresearchresources/mmhcc/default.asp.
chromosome breaks and translocations. Through tar-While comparative histopathology is the current stan-
geted mutation of the Terc gene encoding the RNA sub-dard for evaluating the similarity of a given cancer type
unit of the telomerase enzyme (coupled with multiplein the mouse with that in humans, there is a growing
rounds of backcrossing), DePinho and colleagues haveappreciation that the relationship of the underlying mo-
created strains with more human-sized telomeres andlecular genetic changes may be as, or more important.
which lack the ability to upregulate telomerase. In theThat is, even if tumor progression does not “look”
presence of a p53 mutation, the combination of shortexactly the same in the two species, the genes and
telomeres and no telomerase led to increased tumorpathways affected may be the same or related. In the
incidence and a broader range of tumor types includingemerging era of targeted approaches to therapy and
carcinomas, which only rarely arise in p53/ mice withprevention, the commonality of the molecular events is
normal telomere lengths (Artandi et al., 2000). Impor-of even greater importance. As discussed above, the
tantly, tumors from these animals had a dramaticallymost obvious consideration in this regard is the design
elevated frequency of nonreciprocal translocations,of the initiating mutations (whether they be expression
which are common in human cancer but rare in mice.of specific oncogenes or inactivation of specific TSG or
Fine mapping of such translocations may lead to theDNA repair genes) to most closely mimic those known
discovery of new cancer-associated genes. In a follow-to occur in given human tumor types. Furthermore, with
up study, animals bred to have an ApcMin mutation alongthe availability of high-density gene expression arrays
with telomere dysfunction were more prone to develop-for mouse and human, it is now possible to compare the
ment of early intestinal lesions but had fewer advancedchanges in gene expression patterns that occur during
lesions than ApcMin mice with normal telomeres (Rudolphtumor development in different models and in human
et al., 2001). These data suggest that telomere dysfunc-tumors. An early example of this approach is provided
tion may fuel genetic changes that accelerate tumorby Graveel et al. (2001), who performed such profiling on
initiation, but that the prolonged absence of telomerasechemically induced liver tumors in mice and discovered
function (and attendant genomic instability) can inhibitgene expression changes consistent with human hepa-
tumor progression. The earlier results with p53 null micetocellular carcinoma. Several new technologies aimed
indicate that loss of a DNA damage checkpoint mayat evaluating the state of tumor DNA will also facilitate
be required to facilitate such progression and providesthe comparison of secondary mutations in cancers in
some mechanistic insight into the plausible sequencemice and humans, including genome-wide loss-of-
of mutations in tumorigenesis. For this approach to beheterozygosity screens using single nucleotide poly-
generally useful for cancer modeling, methods must bemorphisms (SNPs), spectral karyotyping (SKY), and
developed to circumvent the need for multiple back-conventional and array-based comparative genomic hy-
crosses to create strains with reduced telomere lengths;
bridization (CGH) (Benaron et al., 1997; Liyanage et al.,
ideally one would also like to be able to reactivate te-
1996; Shi et al., 1997; Hodgson et al., 2001). The charac-
lomerase during the course of tumor progression, as
terization of the molecular signatures of mouse tumors occurs frequently in human cancer.
will also define genes and pathways that are reproduci- Mutation of the Bloom syndrome helicase gene, BLM/
bly affected during tumorigenesis, which is expected to Blm, has been shown to increase rates of mitotic recom-
lead to the discovery of new diagnostic markers for bination in human and mouse. While a Blm mutation
human cancer as well as new therapeutic targets. can lead to embryonic lethality, Luo et al. (2000) have
reported that mice homozygous for the BlmM3 mutation
Some Current Challenges are viable but somewhat tumor prone. When crossed
Promoting Progression to the ApcMin mutation, however, the BlmM3 mutation
As reviewed above, some GEM models have been highly dramatically increased the number of intestinal polyps
useful for studying the biology of tumor progression. and, importantly, many tumors had lost the wild-type
However, a common feature of many mouse tumor mod- Apc allele though mitotic recombination as opposed to
els is that they represent mainly the early stages of the usual mechanism of chromosome loss. Thus, the
disease development and relatively few recapitulate the BlmM3 mutation may represent a useful tool for increas-
features of advanced human cancer, including high fre- ing somatic mutation rates in cancer modeling and at the
quency metastasis. One possible explanation for this same time allow for more precise mapping of recessive
important difference is that the lifespan of the laboratory mutations that contribute to tumor development. Addi-
mouse is two to three years, while tumorigenesis in tional methods for increasing mutation rates in tumor
modeling include the use of retroviruses as insertionalhumans can take several decades to progress to the
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mutagens (Li et al., 1999) and strains deficient in DNA in an in vivo setting in which the activity of the target is
mismatch repair or other repair processes (Edelmann well validated. Beyond assessing the potential utility of
et al., 1999; Shoemaker et al., 2000). targeted therapies, GEM models are also likely to be
Testing Therapies in GEM Models very useful in exploring the effects of many different
A critical unmet need in the development of anticancer compound therapies. Finally, GEM models are also be-
agents is in vivo testing for efficacy. Ideally, before a ginning to be used in the evaluation of potential chemo-
drug, antibody, or other therapeutic agent is put through preventative agents (Alexander, 2000; Green et al.,
the costly and time-consuming process of clinical test- 2001). This is a particularly important application of
ing, its activity would be confirmed in an appropriate these models given the size and duration (and, therefore,
animal model. Unfortunately, for a variety of reasons, the cost) of cancer chemoprevention trials in humans.
in vivo models of choice involve the use of established For experimental therapies and prevention strategies,
human tumor cell lines growing under the skin of immu- the ultimate proof of the utility of GEM models must
nocompromised mice. While these xenograft models await a thorough examination of their performance vis-
have a long history in the pharmaceutical industry, and a`-vis the human clinical experience. Until then, in order
while they are indisputably straightforward to use, their to provide a benchmark for evaluating the new agents,
record of accurately predicting the efficacy of anticancer it would be useful to know how these models respond
agents in the clinic has been questionable. Among other to established therapies with known clinical response
problems, xenograft tumors do not evolve in situ and, rates. Unfortunately, there has been very little activity
thus, lack the appropriate cellular interactions with the in this area. The most compelling work comes from
host microenvironment. Therefore, it is of particular im- the study of myeloid leukemia, in which different GEM
portance to establish whether the new breed of cancer- models have been shown to mimic the response of pa-
prone strains will provide better preclinical models for tients to retinoic acid and arsenic (Rego et al., 2000;
therapy and prevention. It is important to note that some Lallemand-Breitenbach et al., 1999). These studies have
drugs will have pharmacodynamic or pharmacokinetic also provided insight into potentially useful therapeutic
properties in mice that will preclude their testing in any combinations and new strategies (He et al., 2001). Lowe
mouse models. Others will be highly specific to a human and colleagues (Schmitt et al., 1999) have examined
target, which may make GEM models unsuitable for the mechanisms of chemosensitivity and resistance to
testing. However, for the majority of agents, in vivo test- cyclophoshamide treatment in a transgenic model of
ing in an accurate and predictive model is possible and lymphoid malignancy, and Bearss et al. (2000) have
highly desirable. tested the response of different transgenic models of
As discussed above, the requirement of continuous breast cancer to doxorubicin and paclitaxel. Consider-
oncogenic stimulation for tumor maintenance has re- ably more work of this sort is needed to establish
cently been examined, and these studies provide proof whether GEM models will be better suited to predict the
of principle for therapies targeted against particular course of cancer therapy in the future.
gene products or pathways. GEM models have also
been used to examine the efficacy of some targeted The Next Frontier: Imaging
therapies. For example, the anti-Ras compounds in the
As tumor modeling becomes more and more sophisti-
farnesyl transferase inhibitor (FTI) class have been
cated, a major remaining hurdle is the ability to visualize
tested in several models. In most reported cases, FTIs
tumors noninvasively. For preclinical testing in particu-were effective in blocking tumor development or re-
lar, methods must be available that can identify tumor-gressing established tumors (Kohl et al., 1995; Norgaard
bearing mice and then follow tumor responses to ther-et al., 1999; Omer et al., 2000; Reichert et al., 2001);
apy. Already, leukemia models can be monitored byhowever, important negative results were obtained by
blood counts and some tumor types are amenable toShannon and colleagues (Mahgoub et al., 1999) in a
palpation, but for most tumor models, there is a pressingmodel of myeloid leukemia driven by loss of function of
need for improved imaging technologies. Miniaturizedthe Nf1 tumor suppressor gene (an inhibitor of the Ras
versions of conventional cancer imaging methods havepathway). Sawyers and Parsons and their colleagues
been used with some success to visualize mouse tu-(Neshat et al., 2001; Podsypanina et al., 2001) have
mors, including magnetic resonance imaging (MRI), pos-shown that Pten/ cells and tumors from Pten/ mice
itron emission tomography (PET), and computed tomog-have increased activity of the S6 kinase (regulated by
raphy (CT) (Fisher et al., 2001; Hsu et al., 1998; KennelmTOR) and that the rapamycin analog CCI-779 is capa-
et al., 2000; Seitz et al., 2001). Novel approaches thatble of blocking tumor development. The epidermal
rely on the ability to specifically “mark” the tumor cellgrowth factor receptor inhibitor AG-1478 has been
hold even greater promise. For example, one can engi-shown to inhibit Neu-induced mammary tumorigenesis
neer tumor cells to express the green fluorescence pro-(Lenferink et al., 2000). Hanahan and colleagues (Berg-
tein (GFP) for in vivo fluorescence imaging, luciferaseers et al., 1999, 2000) have used the Rip-Tag model
for bioluminescence imaging, specific proteases forto examine the utility of inhibitors of angiogenesis and
cleavage of near infrared imaging probes, or proteinsmatrix metalloproteinases, and, importantly, this work
that bind to or concentrate PET probes (Hoffman, 2001;has demonstrated that the stage of tumor development
Sweeney et al., 1999; Tung et al., 2000; Gambhir et al.,can strongly affect the response. Given that experimen-
2000). These techniques have been pioneered with mod-tal therapies are usually tested initially on critically ill,
ified cell lines and xenograft models, but transgenicend-stage patients, this finding may be of great signifi-
models have also been reported (Herschman et al., 2000;cance for human clinical trial design. These examples
illustrate the power of examining a targeted therapeutic Zhang et al., 2001). Soon, it should be possible to follow
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(1999). Effects of angiogenesis inhibitors on multistage carcinogen-a tumor cell in vivo from its origins through its progres-
esis in mice. Science 284, 808–812.sion to distant metastasis, as well as to assess the re-
Berns, A. (1999). Turning on tumors to study cancer progression.sponses to therapy over time. Armed with these meth-
Nat. Med. 5, 989–990.ods, mouse modelers may truly revolutionize the study
Berns, A. (2001). Cancer. Improved mouse models. Nature 410,of cancer biology and chemotherapy.
1043–1044.
Hann, B., and Balmain, A. (2001). Building ‘validated’ mouse models
Perspective of human cancer. Curr. Opin. Cell Biol. 13, 778–784.
The field of in vivo cancer modeling is moving at a rapid Cavallaro, U., and Christofori, G. (2000). Molecular mechanisms of
pace. While progress toward building more powerful tumor angiogenesis and tumor progression. J. Neuro-Oncology 50,
and more accurate mouse models of human cancer has 63–70.
been significant in the recent past, one strongly sus- Cavallaro, U., Niedermeyer, J., Fuxa, M., and Christofori, G. (2001).
N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-pects that the best is yet to come. From the functional
receptor signalling. Nat. Cell Biol. 3, 650–657.dissection of cancer genes and pathways to the discov-
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy,ery of new markers of disease and better therapies, the
N., Shen, Q., O’Hagan, R., Pantginis, J., Zhou, H., et al. (1999).mouse is expected to play an even more vital role in the
Essential role for oncogenic Ras in tumour maintenance. Naturefuture of cancer research. For even as the strategies
400, 468–472.
of mouse making described above are reported in the
Cichowski, K., Shih, T.S., Schmitt, E., Santiago, S., Reilly, K.,
literature, new and more sophisticated methods are be- McLaughlin, M.E., Bronson, R.T., and Jacks, T. (1999). Mouse mod-
ing developed. Perhaps it takes more than sweaty shirts els of tumor development in neurofibromatosis type 1. Science 286,
to make a mouse these days, but it is certainly well 2172–2176.
worth the effort. Clarke, A.R. (2000). Manipulating the germline: its impact on the
study of carcinogenesis. Carcinogenesis 21, 435–441.
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